A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs RG 7880 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions
- Sponsors Genentech
- 23 Mar 2018 Planned End Date changed from 6 Oct 2018 to 21 Nov 2018.
- 23 Mar 2018 Planned primary completion date changed from 6 Oct 2018 to 21 Nov 2018.
- 21 Feb 2018 Planned End Date changed from 21 May 2018 to 6 Oct 2018.